BioCentury
ARTICLE | Clinical News

VBI's CMV vaccine induces 100% seroconversion in Phase I

August 4, 2017 7:50 PM UTC

VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV) reported interim data from a single-blind, Canadian Phase I trial in 128 cytomegalovirus (CMV)-negative healthy volunteers showing that 2 μg intramuscular VBI-1501A (CMV eVLP) with aluminum phosphate adjuvant led to seroconversion in 100% of subjects at 1 month after 2 of 3 planned vaccinations. Subjects received 3 vaccinations of placebo; 0.5, 1 or 2 μg VBI-1501A with alum; or 1 μg VBI-1501 without alum at baseline, 2 months and 6 months. Additionally, neutralizing antibodies against epithelial cell infection were reported in 17% of subjects receiving the highest dose of VBI-1501A. VBI-1501A was well tolerated...

BCIQ Company Profiles

VBI Vaccines Inc.